Telomir Pharmaceuticals (TELO) has caught the attention of institutional investors, with JPMorgan Chase & Co. (JPM) significantly increasing its position in the company during the fourth quarter. According to its latest SEC filing, JPMorgan raised its holdings by an impressive 1,096.4%, acquiring 37,980 additional shares to bring its total ownership to 41,444 shares—valued at approximately $171,000. This represents about 0.14% of the company.
Other major institutions have also adjusted their positions. Rhumbline Advisers doubled its stake, Barclays PLC tripled its holdings, and Corebridge Financial saw an increase of nearly 274%. Virtu Financial LLC entered a new position, while Bank of New York Mellon Corp (BK) grew its holdings by 40.8%, now owning 72,295 shares worth $298,000.
The surge in institutional interest may signal growing confidence in Telomir’s prospects as the company continues to develop its pharmaceutical pipeline. Investors will be watching closely to see if this trend continues.
You might like this article:KindlyMD and Nakamoto Merge to Launch Largest Bitcoin Treasury Initiative in Public Markets
